– SWEDEN, Solna – InDex Pharmaceuticals Holding AB (STO: INDEX) today announced the appointment of Jenny Sundqvist as the new CEO, replacing acting CEO Johan Giléus who will continue as CFO.
“We are very pleased to welcome Jenny Sundqvist as the new CEO of InDex Pharmaceuticals. Jenny’s knowledge and experience in pharmaceutical development and business management will be of great benefit for further development of the company, and I also want to take the opportunity to thank Johan for his appreciated and valuable contributions to the company as acting CEO,” said Board Chairamn, Wenche Rolfsen.
About Jenny Sundqvist
Jenny Sundqvist comes from a position as CCO at Isofol Medical AB and has broad experience in leading positions within the pharmaceutical industry. Jenny Sundqvist has an impressive track record of developing companies and creating value. She has broad experience in leading successful research organizations in combination with commercial experience in the marketing of approved medications. Jenny has previously, among other things, worked as CCO at Isofol Medical AB, been responsible for AstraZeneca’s global research portfolio in oncology, worked as Site Director for AstraZeneca’s research unit in Gothenburg, and been global brand manager for AstraZeneca’s asthma product Symbicort.
“I am very grateful to have been entrusted by the Board of Directors to lead InDex on this exciting journey of taking cobitolimod through phase III and towards the market. I look forward to working with the Board of Directors and the competent employees at InDex to improve the quality of life for patients while building value for the shareholders,” said Jenny Sundqvist.
About InDex Pharmaceuticals
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences, with the potential to be used in the treatment of various immunological diseases.
InDex is based in Stockholm, Sweden.
For more information: https://www.indexpharma.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
